Management of patients with adrenal 382 cancer: recommendations of an international consensus conference, Endocr Relat Cancer, vol.383, issue.12, pp.667-680, 2005. ,
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.23, issue.suppl 7, pp.131-138, 2012. ,
DOI : 10.1093/annonc/mds231
Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?, Hormones and Cancer, vol.142, issue.1, pp.363-371, 2011. ,
DOI : 10.1007/s12672-011-0094-2
Combination Chemotherapy in Advanced Adrenocortical Carcinoma, New England Journal of Medicine, vol.366, issue.23, pp.2189-2197, 2012. ,
DOI : 10.1056/NEJMoa1200966
Adjuvant therapy in patients with adrenocortical 393 carcinoma: a position of an international panel, J Clin Oncol Off J Am Soc Clin Oncol, vol.394, issue.28, pp.401-402, 2010. ,
Adjuvant therapies and patient and tumor 396 characteristics associated with survival of adult patients with adrenocortical carcinoma, J Clin, vol.397, 2014. ,
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients, British Journal of Cancer, vol.69, issue.5, pp.947-951, 1994. ,
DOI : 10.1038/bjc.1994.183
Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p?DDD) levels on the treatment of patients with adrenocortical carcinoma, Cancer, vol.62, issue.6, pp.1385-1392, 2001. ,
DOI : 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2
Prognostic markers of survival after 404 combined mitotane-and platinum-based chemotherapy in metastatic adrenocortical carcinoma 405 (ACC), Endocr Relat Cancer, pp.10-1677, 2010. ,
The long-term survival in 407 adrenocortical carcinoma with active surgical management and use of monitored mitotane, 2010. ,
Plasma Concentrations of o,p???DDD, o,p???DDA, and o,p???DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.6, pp.1844-1851, 1210. ,
DOI : 10.1210/jc.2010-2676
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center, European Journal of Endocrinology, vol.169, issue.6, pp.891-899, 2013. ,
DOI : 10.1530/EJE-13-0519
The treatment of adrenocortical 417 carcinoma with o,p'-DDD: prognostic implications of serum level monitoring, Eur J Cancer, p.418, 1984. ,
Studies of the pharmacology of o,p'DDD in man, J Lab Clin Med, vol.58, pp.296-304, 1961. ,
Identification of o,p'- 421 dichlorodiphenyl acetic acid as a urinary metabolite of 1-(o-chlorophenyl, p.1, 1972. ,
Metabolism of 1-(0-chlorophenyl)-1-(p-chlorophenyl)-2,2- 424 dichloroethane (o,p'-DDD) in rats, Drug Metab Dispos Biol Fate Chem, vol.3, pp.15-25, 1975. ,
Adjuvant mitotane therapy of adrenal cancer -use and controversy. N Engl 426, J Med, vol.356, pp.2415-2418, 2007. ,
Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p- 428 chlorophenyl)-2,2-dichloroethane (o,p,'-DDD) Correlation between adrenocorticolytic 429 activity and metabolic activation by adrenocortical mitochondria, Drug Metab Dispos Biol, vol.430, 1980. ,
In vitro and in vivo metabolism of a radioiodinated analog of 1- 432 (2-chlorophenyl)-1-(4-chlorophenyl)-2,-dichloroethane, Drug Metab Dispos Biol Fate Chem, vol.433, issue.13, pp.113-115, 1985. ,
The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2- 435 dichloroethane (o,p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to 436 mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect, 1977. ,
Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p???-DDD] and its p,p???- and m,p???-isomers, Biochemical Pharmacology, vol.49, issue.10, pp.1483-1489, 1995. ,
DOI : 10.1016/0006-2952(95)00028-X
Metabolic Activation and Binding of Mitotane in Adrenal Cortex Homogenates, Journal of Pharmaceutical Sciences, vol.84, issue.2, pp.134-138, 1995. ,
DOI : 10.1002/jps.2600840203
Adrenal proteins bound by a reactive intermediate of mitotane, Cancer Chemotherapy and Pharmacology, vol.39, issue.6, pp.537-540, 1997. ,
DOI : 10.1007/s002800050610
Mitotane alters mitochondrial respiratory chain 446 activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat 447, Cancer, vol.20, pp.371-381, 2013. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 1990. ,
DOI : 10.1016/j.ejca.2008.10.026
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up, European Journal of Endocrinology, vol.166, issue.2, pp.261-268, 2012. ,
DOI : 10.1530/EJE-11-0557
Comparison of two mitotane starting dose 456 regimens in patients with advanced adrenocortical carcinoma, J Clin Endocrinol Metab, vol.457, issue.98, pp.4759-4767, 2013. ,
The effect of mitotane on viability, 459 steroidogenesis and gene expression in NCI?H295R adrenocortical cells, Mol Med Rep, vol.460, issue.7, pp.893-900, 2013. ,
Morpho-functional effects of mitotane on mitochondria 462 in human adrenocortical cancer cells, Endocr Relat Cancer, 2013. ,
Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5??-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.1, pp.161-1712012, 2013. ,
DOI : 10.1210/jc.2012-2851
Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor, Journal of Endocrinology, vol.216, issue.3, pp.297-305, 2013. ,
DOI : 10.1530/JOE-12-0297
Influence of the CYP2B6 polymorphism on the 470 pharmacokinetics of mitotane Management of Addison's disease in adrenalectomized 473 patients, Pharmacogenet Genomics Bull N Y Acad Med, vol.23, issue.29, pp.293-300295, 1953. ,
Structural requirements for mitotane 475 activity: development of analogs for treatment of adrenal cancer, Anticancer Res, vol.32, pp.2711-476, 2012. ,
Chiral effects in adrenocorticolytic action of 478 o,p'-DDD (mitotane) in human adrenal cells, Xenobiotica Fate Foreign Compd Biol Syst, vol.479, issue.40, pp.177-183, 2010. ,
DDD concentration in cell culture medium at time zero (T0) Each 542 experiment was repeated 3 to 5 times. H295R cell uptake represents 40% of initial o,p'DDD yet 543 o,p'DDA was not recovered in the cell pellet whether H295R cells were incubated with o,p'DDD or 544 o, DDA. *P<0.05 and **P<0.01, Mann-Whitney U test ,